WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...

Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...

Duchenne muscular dystrophy patient died after being treated with the gene therapy delandistrogene moxeparvovec (Elevidys), ...

Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...

Sarepta Therapeutics (NASDAQ:SRPT) reported a second fatality from acute liver failure in a patient treated with its gene ...

In the U.S., ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD ... You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

May 21, 2025--(BUSINESS WIRE)--Sarepta Therapeutics ... rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. We have received feedback from the Medicines ...

Sarepta Therapeutics experienced a share price increase of 10% over the last week, possibly affected by significant advancements in its gene therapy for Duchenne muscular dystrophy (DMD).

--(BUSINESS WIRE)-- Sarepta Therapeutics ... rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. We have received feedback from the Medicines & Healthcare products ...